23 September 2025
23 September 2025 B.P. Marsh & Partners Plc (“B.P. Marsh”, the “Company” or the “Group”) Trading Update B.P. Marsh & Partners Plc (AIM: BPM),…
23 September 2025 RECOMMENDED ALL-SHARE COMBINATION OF OCEAN WILSONS HOLDINGS LIMITEDAND HANSA INVESTMENT COMPANY LIMITED ADJOURNMENT OF COURT SANCTION HEARING On 28 July 2025,…
18 September 2025
Renishaw plc 18 September 2025 Preliminary announcement of results for the year ended 30 June 2025 FY2025 highlightsRecord revenue and…
17 September 2025
Games Workshop Group PLC (the “Company”) DIVIDEND Games Workshop, the maker of Warhammer, announces that trading to 31 August 2025 is in line with the…
17 September 2025 YOUNG & CO.’S BREWERY, P.L.C. (“Young’s”) Trading update Young’s, the premium operator of pubs and bedrooms, today provides an update on…
Saphnelo self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis Subcutaneous administration of first-in-class biologic…
Update on the RESOLUTE Phase III trial for Fasenra in chronic obstructive pulmonary disease The RESOLUTE Phase III trial of AstraZeneca’s Fasenra (benralizumab), despite showing numerical improvement, did…
Advanced Medical Solutions Group plc (“AMS” or the “Group”) Interim results for the six months ended 30 June 2025 ~ H1 delivering high quality…